IFF says it’s highly focused on unique formats like chocolate bars, beverages, and gummies that extend delivery possibilities beyond traditional tablets and capsules.
IFF (New York City) will highlight its combination of novel delivery formats and branded ingredients at next week’s Natural Products Expo West trade show in Anaheim, CA. The company will be exhibiting at booth #2533.
Samples the company will premiere at the show include: 1) an immune-boosting peach mango stick pack featuring the company’s Howaru Protect Adult Bifidobacterium lactis BI-04 probiotic strain plus a Pure Source vitamin blend from its PowderPure line and its Tastepoint natural flavors, 2) a coffee-flavored brain health bar containing the company’s Neuravena green oat extract and PowderPure cold-brew coffee, and 3) chai-flavored digestive health chocolates touting the company’s Howaru Kids Digestive Health B. lactis HN019 strain and PowderPure ginger.
IFF says it’s highly focused on unique formats like chocolate bars, beverages, and gummies that extend delivery possibilities beyond traditional tablets and capsules. In a press release, Jennifer Montgomery, global marketing leader, IFF, said, “In 2021, there was a 33% increase in consumers treating food as medicine, compared to 2020. This trend is likely to continue in 2022 as more consumers seek unique, delicious solutions that support their overall health. We’re looking forward to collaborating with customers on-site to pinpoint which ingredients, formats, tastes, and scents are the right fit for their brand.”
Other unique IFF ingredient blends on display will be Howaru Feminine Health with PowderPure Cranberry for women’s health, Howaru Protect Adult with Echinacea EFLA 894 for immune support, and Howaru Calm with Sharp-PS for brain health. Plus, the company will present new clinical data on Neuravena green oat extract, its fast-acting nootropic ingredient.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.